MX2019004364A - Formulaciones en gel intranasal de testosterona en dosis de menor potencia y uso de las mismas para el tratamiento de la anorgasmia o el trastorno de deseo sexual hipoactivo. - Google Patents

Formulaciones en gel intranasal de testosterona en dosis de menor potencia y uso de las mismas para el tratamiento de la anorgasmia o el trastorno de deseo sexual hipoactivo.

Info

Publication number
MX2019004364A
MX2019004364A MX2019004364A MX2019004364A MX2019004364A MX 2019004364 A MX2019004364 A MX 2019004364A MX 2019004364 A MX2019004364 A MX 2019004364A MX 2019004364 A MX2019004364 A MX 2019004364A MX 2019004364 A MX2019004364 A MX 2019004364A
Authority
MX
Mexico
Prior art keywords
lower dosage
gel formulations
dosage strength
testosterone gel
intranasal
Prior art date
Application number
MX2019004364A
Other languages
English (en)
Inventor
Kreppner Wayne
Fogarty Siobhan
Oberegger Werner
José Pierre Marie Maes Paul
Original Assignee
Trimel Biopharma Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trimel Biopharma Srl filed Critical Trimel Biopharma Srl
Publication of MX2019004364A publication Critical patent/MX2019004364A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Otolaryngology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a formulaciones pernasales en dosis menores de gel de testosterona para la administración intranasal y métodos de tratamiento para usar las formulaciones pernasales de gel de testosterona en dosis menores para el tratamiento de un sujeto femenino con anorgasmia y/o trastorno de deseo sexual hipoactivo.
MX2019004364A 2011-05-13 2013-11-13 Formulaciones en gel intranasal de testosterona en dosis de menor potencia y uso de las mismas para el tratamiento de la anorgasmia o el trastorno de deseo sexual hipoactivo. MX2019004364A (es)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US201161518903P 2011-05-13 2011-05-13
US201161518916P 2011-05-13 2011-05-13
US201161518913P 2011-05-13 2011-05-13
US201161518921P 2011-05-13 2011-05-13
US201161486252P 2011-05-14 2011-05-14
US201161486251P 2011-05-14 2011-05-14
US201161486266P 2011-05-14 2011-05-14
US201161486254P 2011-05-14 2011-05-14
US201161513495P 2011-07-29 2011-07-29
US201161513497P 2011-07-29 2011-07-29
US201161513499P 2011-07-29 2011-07-29
US201261598336P 2012-02-13 2012-02-13
US201261598329P 2012-02-13 2012-02-13
US201261598335P 2012-02-13 2012-02-13
US201261598333P 2012-02-13 2012-02-13

Publications (1)

Publication Number Publication Date
MX2019004364A true MX2019004364A (es) 2019-08-05

Family

ID=46513792

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019013864A MX2019013864A (es) 2011-05-13 2013-11-13 Formulaciones en gel intranasal de testosterona en dosis de menor potencia y uso de las mismas para el tratamiento de la anorgasmia o el trastorno de deseo sexual hipoactivo.
MX2019004364A MX2019004364A (es) 2011-05-13 2013-11-13 Formulaciones en gel intranasal de testosterona en dosis de menor potencia y uso de las mismas para el tratamiento de la anorgasmia o el trastorno de deseo sexual hipoactivo.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019013864A MX2019013864A (es) 2011-05-13 2013-11-13 Formulaciones en gel intranasal de testosterona en dosis de menor potencia y uso de las mismas para el tratamiento de la anorgasmia o el trastorno de deseo sexual hipoactivo.

Country Status (11)

Country Link
EP (1) EP2706985B1 (es)
JP (4) JP6562630B2 (es)
KR (2) KR20140033407A (es)
CN (2) CN103687587A (es)
AU (4) AU2012257491A1 (es)
CA (1) CA2835911C (es)
EA (1) EA201391702A1 (es)
ES (1) ES2825799T3 (es)
IL (1) IL229322A0 (es)
MX (2) MX2019013864A (es)
WO (1) WO2012156821A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130040923A1 (en) 2011-05-13 2013-02-14 Trimel Pharmaceuticals Corporation Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US20130045958A1 (en) 2011-05-13 2013-02-21 Trimel Pharmaceuticals Corporation Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US9757388B2 (en) 2011-05-13 2017-09-12 Acerus Pharmaceuticals Srl Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
US11744838B2 (en) 2013-03-15 2023-09-05 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
US20160279146A1 (en) * 2013-11-11 2016-09-29 Limoxifen B.V. Methods and pharmaceutical formulations for treatment of selective estrogen-receptor modulator-induced adverse drug reactions
AU2017274649B2 (en) 2016-06-03 2023-02-02 M et P Pharma AG Nasal pharmaceutical compositions with a porous excipient
WO2018134783A1 (en) * 2017-01-20 2018-07-26 M et P Pharma AG Nasal pharmaceutical compositions for reducing the risks of exposure to air pollutants
WO2019175290A1 (en) 2018-03-13 2019-09-19 Beckley Canopy Therapeutics Limited Cannabis or cannabis derived compositions for promoting cessation of chemical dependence

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4214953C2 (de) 1992-05-06 1995-05-18 Arrowdean Ltd Arzneimittel zur Erhöhung des Testosteronspiegels
US5756071A (en) 1992-06-03 1998-05-26 Arrowdean Limited Method for nasally administering aerosols of therapeutic agents to enhance penetration of the blood brain barrier
US6737084B2 (en) 2000-06-27 2004-05-18 Qualilife Compositions and methods for enhancing or treating female sexual response
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
DE60303854T2 (de) * 2003-11-11 2006-08-10 Mattern, Udo Nasenformulierung mit kontrollierter Freisetzung von Sexualhormonen
JP2008536851A (ja) * 2005-04-13 2008-09-11 ユニメド ファーマスーティカルズ インク 女性でテストステロンおよび関連ステロイドの濃度を増加させる方法
EP1790343A1 (en) * 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
EP2068825B1 (en) 2006-10-04 2011-01-26 M & P Patent Aktiengesellschaft Controlled release delivery system for nasal application of neurotransmitters
KR101083696B1 (ko) * 2007-09-20 2011-11-15 가부시키가이샤 시세이도 경피 흡수 제제

Also Published As

Publication number Publication date
AU2019203066A1 (en) 2019-05-30
AU2020264363A1 (en) 2020-12-03
IL229322A0 (en) 2014-01-30
MX2019013864A (es) 2020-01-20
AU2020264363B2 (en) 2022-09-15
CN109528626A (zh) 2019-03-29
KR20190006034A (ko) 2019-01-16
CA2835911A1 (en) 2012-11-22
EA201391702A1 (ru) 2014-10-30
JP2021042236A (ja) 2021-03-18
JP2017101057A (ja) 2017-06-08
AU2017204184A1 (en) 2017-07-20
KR102063003B1 (ko) 2020-01-06
JP6562630B2 (ja) 2019-08-21
CA2835911C (en) 2022-08-30
ES2825799T3 (es) 2021-05-17
EP2706985B1 (en) 2020-07-22
JP2014513147A (ja) 2014-05-29
AU2012257491A1 (en) 2013-12-12
WO2012156821A1 (en) 2012-11-22
KR20140033407A (ko) 2014-03-18
CN103687587A (zh) 2014-03-26
EP2706985A1 (en) 2014-03-19
JP6929076B2 (ja) 2021-09-01
JP2019081780A (ja) 2019-05-30

Similar Documents

Publication Publication Date Title
MX2019004364A (es) Formulaciones en gel intranasal de testosterona en dosis de menor potencia y uso de las mismas para el tratamiento de la anorgasmia o el trastorno de deseo sexual hipoactivo.
MX356525B (es) Vectores de virus asociados con adeno (aav) para uso en terapia de genes de coroideremia.
PH12015500525A1 (en) Formulations of enzalutamide
HK1223301A1 (zh) 基於鼻內遞送中和抗體以增强治療效力的組合物和方法
PL2704704T3 (pl) Bakterie probiotyczne do miejscowego leczenia zaburzeń skóry
MY176031A (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
MY168032A (en) Warm-Cool Beauty Treatment Device
MX2019001977A (es) Metodos y composiciones para tratar esclerosis multiple y trastornos relacionados.
MX357656B (es) Alfa-1-microglobulina para usarse en tratamiento de enfermedades relacionadas a mitocondrias.
SG10201804034QA (en) Methods for treating hypotension
MX2020009966A (es) Formas de dosificacion y usos terapeuticos de la l-4-cloro quinurenina.
IL233225A0 (en) Methods and formulations for the treatment of sialic acid deficiencies
MX356317B (es) Tratamiento de síntomas asociados a gastroparesia femenina.
MX2013010367A (es) Composiciones y metodos para la terapia y diagnostico de influenza.
WO2014083432A3 (en) Female intranasal testosterone gel for treating anorgasmia
MX354989B (es) Regimenes de tratamiento.
MX2015001695A (es) Regimenes de tratamiento.
IN2014KN01772A (es)
MX369774B (es) Uso de pregn-4-en-20-in-3-ona para el tratamiento de trastornos depresivos.
ZA201309052B (en) Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
UA61823U (ru) Применение гамма-оксимасляной кислоты как стимулятора ускорения скорости регенерации и восстановления силы мышечных сокращений
MX2013006633A (es) Beta-hidroxi-gamma-aminofosfonatos para el tratamiento de trastornos inmunes.
HUP1300025A2 (hu) Készítmény az UVB-fényterápia hatékonyságának fokozására, eljárás annak elõállítására és alkalmazása
NZ745950A (en) Methods and compositions for treating multiple sclerosis and related disorders
UA67953U (ru) Установка для лечения вирусных гепатитов с использованием медицинского озона